The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy.

MLA

Tani, Shigemasa, et al. “The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid May Be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy.” American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, vol. 17, no. 5, Oct. 2017, pp. 409–20. EBSCOhost, https://doi.org/10.1007/s40256-017-0238-z.

APA

Tani, S., Nagao, K., Kawauchi, K., Yagi, T., Atsumi, W., Matsuo, R., & Hirayama, A. (2017). The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy. American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, 17(5), 409–420. https://doi.org/10.1007/s40256-017-0238-z

Chicago

Tani, Shigemasa, Ken Nagao, Kenji Kawauchi, Tsukasa Yagi, Wataru Atsumi, Rei Matsuo, and Atsushi Hirayama. 2017. “The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid May Be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy.” American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 17 (5): 409–20. doi:10.1007/s40256-017-0238-z.